Thymalin

Unregulated

Also known as: Thymic peptide extract, Thymus extract

Immune & Longevity

Last reviewed: April 28, 2026

A thymic peptide bioregulator developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Thymalin is a complex of polypeptides extracted from the thymus gland that has been used clinically in Russia since the 1980s for immune restoration. Khavinson's research group reported that thymalin treatment in elderly patients was associated with reduced mortality over a 6-year follow-up period.

Mechanism of Action

Contains a mixture of thymic peptides that restore T-cell function and thymic output. Proposed to act through epigenetic mechanisms, reactivating genes involved in immune function that become silenced with aging. May promote thymic regeneration and restore the balance between T-helper and T-suppressor cells.

Common Uses

  • Immune system restoration in elderly patients
  • Post-infection immune recovery
  • Anti-aging and longevity protocols
  • Adjunct to cancer immunotherapy (in Russian clinical practice)

Known Risks

  • Limited Western clinical data
  • Most research from Russian institutions — peer review concerns
  • Allergic reactions possible (animal-derived extract)
  • Quality varies significantly between sources

Regulatory Status

Unregulated

Not FDA-approved or recognized. Used clinically in Russia and some CIS countries. No FDA category. Available only as a research peptide in the US. Khavinson's longevity claims, while published, have not been replicated in Western clinical trials.

Common Protocols

Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.

Intramuscular injection

Typical Dose

10 mg

Frequency

Daily for 5–10 days

Cycle Length

1–2 courses per year

Khavinson protocol: 10 mg IM daily for 5–10 days, repeated 1–2 times per year. Often combined with epithalon in Russian longevity protocols. The short course duration is characteristic of bioregulator peptide therapy.

Related Compounds

Research References

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.